The advent of Precision Medicine has globally revolutionized the approach of translational research suggesting a patient-centric vision with therapeutic choices driven by the identification of specific predictive biomarkers of response to avoid ineffective therapies and reduce adverse effects. The spread of "multi-omics" analysis and the use of sensors, together with the ability to acquire clinical, behavioral, and environmental information on a large scale, will allow the digitization of the state of health or disease of each person, and the creation of a global health management system capable of generating real-time knowledge and new opportunities for prevention and therapy in the individual person (high-definition medicine). Real world data-based translational applications represent a promising alternative to the traditional evidence-based medicine (EBM) approaches that are based on the use of randomized clinical trials to test the selected hypothesis. Multi-modality data integration is necessary for example in precision oncology where an Avatar interface allows several simulations in order to define the best therapeutic scheme for each cancer patient.

De Maria Marchiano, R., Di Sante, G., Piro, G., Carbone, C., Tortora, G., Boldrini, L., Pietragalla, A., Daniele, G., Tredicine, M., Cesario, A., Valentini, V., Gallo, D., Babini, G., D'oria, M., Scambia, G., Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go, <<JOURNAL OF PERSONALIZED MEDICINE>>, 2021; 11 (3): 216-N/A. [doi:10.3390/jpm11030216] [http://hdl.handle.net/10807/174975]

Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go

De Maria Marchiano, Ruggero;Di Sante, Gabriele
;
Tortora, Giampaolo;Boldrini, Luca;Daniele, Gennaro;Tredicine, Maria;Cesario, Alfredo;Valentini, Vincenzo;Scambia, Giovanni
2021

Abstract

The advent of Precision Medicine has globally revolutionized the approach of translational research suggesting a patient-centric vision with therapeutic choices driven by the identification of specific predictive biomarkers of response to avoid ineffective therapies and reduce adverse effects. The spread of "multi-omics" analysis and the use of sensors, together with the ability to acquire clinical, behavioral, and environmental information on a large scale, will allow the digitization of the state of health or disease of each person, and the creation of a global health management system capable of generating real-time knowledge and new opportunities for prevention and therapy in the individual person (high-definition medicine). Real world data-based translational applications represent a promising alternative to the traditional evidence-based medicine (EBM) approaches that are based on the use of randomized clinical trials to test the selected hypothesis. Multi-modality data integration is necessary for example in precision oncology where an Avatar interface allows several simulations in order to define the best therapeutic scheme for each cancer patient.
Inglese
De Maria Marchiano, R., Di Sante, G., Piro, G., Carbone, C., Tortora, G., Boldrini, L., Pietragalla, A., Daniele, G., Tredicine, M., Cesario, A., Valentini, V., Gallo, D., Babini, G., D'oria, M., Scambia, G., Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go, <>, 2021; 11 (3): 216-N/A. [doi:10.3390/jpm11030216] [http://hdl.handle.net/10807/174975]
File in questo prodotto:
File Dimensione Formato  
jpm-11-00216.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.04 MB
Formato Adobe PDF
1.04 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/174975
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 17
social impact